Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on Equity

Seres Therapeutics (MCRB) Return on Capital Employed (2016 - 2025)

Seres Therapeutics' Return on Capital Employed history spans 11 years, with the latest figure at 0.85% for Q3 2025.

  • For Q3 2025, Return on Capital Employed rose 33.0% year-over-year to 0.85%; the TTM value through Sep 2025 reached 0.85%, up 33.0%, while the annual FY2024 figure was 0.58%, 18.0% up from the prior year.
  • Return on Capital Employed for Q3 2025 was 0.85% at Seres Therapeutics, up from 0.89% in the prior quarter.
  • Across five years, Return on Capital Employed topped out at 0.14% in Q3 2021 and bottomed at 1.18% in Q3 2024.
  • The 5-year median for Return on Capital Employed is 0.73% (2023), against an average of 0.66%.
  • The largest annual shift saw Return on Capital Employed skyrocketed 86bps in 2023 before it plummeted -96bps in 2024.
  • A 5-year view of Return on Capital Employed shows it stood at 0.22% in 2021, then crashed by -234bps to 0.74% in 2022, then grew by 1bps to 0.73% in 2023, then plummeted by -41bps to 1.03% in 2024, then grew by 17bps to 0.85% in 2025.
  • Per Business Quant, the three most recent readings for MCRB's Return on Capital Employed are 0.85% (Q3 2025), 0.89% (Q2 2025), and 0.95% (Q1 2025).